Borteco 2mg Injection

Borteco 2mg Injection is a chemotherapeutic medication belonging to the class of proteasome inhibitors. It contains bortezomib 2mg and is used to treat multiple myeloma and mantle cell lymphoma. This medication is used together with other chemotherapy medicines such as pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone or thalidomide for patients with newly diagnosed disease or those who are ineligible for or have not undergone blood stem cell transplant treatment.

Do not use Borteco 2mg Injection if you are allergic to bortezomib or any other ingredient in this medicine. Use is not advised in patients with a compromised immune system. Inform your doctor if you have an active infection before starting treatment. Use in children and adolescents is not recommended. Use is not recommended in patients with hepatitis.

Inform your doctor before starting treatment if you have gastrointestinal disorders, hepatic disorders, thrombocytopenia (low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities occurring during cancer treatment), neuropathy (nerve malfunction), cardiac disorders, severe lung problems, pulmonary disorders or posterior reversible encephalopathy syndrome.

Monitor blood counts and hepatic enzymes throughout the treatment period. Use during pregnancy and breastfeeding is not recommended. The doctor will determine use only if absolutely necessary, as it may cause harm to the developing foetus. Effective contraceptive methods are recommended during therapy and for 3 months after completion. Inform your doctor if you are pregnant or planning to become pregnant to discuss effective contraceptive options.

Inform your physician about all medicines, over-the-counter drugs, vitamins and herbal supplements you are taking before starting therapy.

The Borteco 2mg Injection is used in the following: Treatment of multiple myeloma Treatment of mantle cell lymphoma

Borteco 2mg Injection works by exerting a toxic effect on cancer cells. It inhibits the 26S proteasome and blocks a major cell signalling pathway. This inhibition of the signalling pathway makes the cancer cells sensitive to chemotherapy. By inhibiting the proteasome, Borteco 2mg Injection disrupts the normal process of protein degradation within the cell. This leads to the accumulation of misfolded or damaged proteins, which are toxic to the cell. The accumulation of misfolded proteins triggers a series of cellular responses, including the activation of stress pathways and the induction of apoptosis. This medicine also enhances the build-up of a protein and minimises cancer cell growth and multiplication.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious side effects of Borteco 2mg Injection are: Peripheral neuropathy Hypotension Cardiac toxicity Posterior Reversible Encephalopathy Syndrome (PRES) Tumor Lysis Syndrome Hepatic Toxicity Thrombotic Microangiopathy Common side effects of Borteco 2mg Injection are: Loss of appetite Sensitivity, tingling and burning sensation of the skin Nausea, vomiting, and diarrhea Mouth ulcers Constipation Muscle and bone pain Hair loss Fever Reduction in blood cell count Reduced kidney function Shivering Infections Dehydration Stomach problems Difficulty sleeping, anxiety, mood swings, depressed mood

Borteco 2mg Injection should be given only by a trained healthcare professional, usually through subcutaneous or intravenous injection. Inform your doctor if you have nerve problems, as Bortezomib can worsen peripheral neuropathy. Drink plenty of fluids to stay hydrated and reduce the risk of side effects like low blood pressure. Avoid live vaccines and close contact with sick individuals during treatment to reduce infection risk. Immediately report symptoms like numbness, tingling, fatigue, or unusual bruising to your doctor.